June 2025 in “Journal of Applied Toxicology” Finasteride may protect diabetic rats from oxidative stress and inflammation.
June 2025 in “JEADV Clinical Practice” Scarring alopecia is linked to higher rates of vitamin D deficiency, metabolic issues, mental health problems, thyroid disease, and other health conditions.
Hulunbuir lambs adapt better to cold than Hu lambs, showing more wool growth and thicker skin.
March 2025 in “Anatomy & Cell Biology” Hair follicle stem cell secretions may help protect brain cells and improve stroke recovery.
February 2025 in “International Journal of Molecular Sciences” Alkaloids help fight influenza in animals but need more research for human use.
January 2025 in “Journal of Food Biochemistry” 2′‐Fucosyllactose reduces hair loss and promotes hair growth in mice.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
May 2023 in “Cytotherapy” Hair follicle and adipose cell vesicles both protect neurons and reduce inflammation similarly.
June 2022 in “Organic communications” Natural compounds, especially Withaferin-A, may help treat post-COVID-19 complications, but some may have side effects.
A new compound from Royoporus badius activates immune cells and induces inflammatory responses.
May 2010 in “Dermatologic Clinics” The document concludes that new treatments for skin conditions are complex but effective, including spironolactone for female hair loss and propranolol for infantile hemangiomas.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
January 1983 in “Side effects of drugs annual” Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.